Vimarsana
Biggest News Aggregation in the World

Page 11 - Subgroup Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Subgroup Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Subgroup Analysis Today - Breaking & Trending Today

Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022 - Vimarsana News

Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the...

Saluda Medical Announces Robust Scientific Presence at 2022 International Neuromodulation Society (INS) World Congress - Vimarsana News

Saluda Medical Announces Robust Scientific Presence at 2022 International Neuromodulation Society (INS) World Congress

/PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation with an emerging...

Urovant Sciences, Inc.: Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA in Dry and Wet Overactive Bladder Populations - Vimarsana News

Urovant Sciences, Inc.: Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA in Dry and Wet Overactive Bladder Populations

Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB) Article appears

AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting - Vimarsana News

AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting

-- AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectru...

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up - Vimarsana News

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

/PRNewswire/ -- Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular...